In 2024 alone, the FDA approved 50 novel therapies, supported by about 31,000 participants in pivotal trials. This is a powerful base of evidence, but it i...
Sanofi’s subcutaneous Sarclisa Escena approved in the US as first anticancer treatment administered via on-body injector Sarclisa Escena admini...
Elevar Therapeutics, Inc., a majority-owned subsidiary of HLB Co., Ltd. and a fully integrated biopharmaceutical company dedicated to elevating treatment...
BriaCell is advancing a new generation of cancer immunotherapies designed to improve outcomes for patients with metastatic breast cancer and other solid tu...
SL Science Holding Limited (“SL Science” or the “Company”) (Nasdaq: SLBT), a Taiwan-headquartered biomedical company specializing...
Synergy was demonstrated in a combination arm of GLIX1 and the PARP inhibitor olaparib at low doses, with substantially better efficacy compared t...
Keenova Therapeutics plc announced positive results from its Phase 3 clinical trial of XIAFLEX® (collagenase clostridium histolyticum) for the ...
Vaxart, Inc. announced topline data from the approximately 400-participant sentinel safety cohort of its Phase 2b clinical trial evaluating the Company&r...
TEPKINLY® (epcoritamab) plus lenalidomide and rituximab (R2) is the first and only bispecific-based therapy approved in Europe for the treatment of...
InnoCare Pharma (HKEX: 09969; SSE: 688428), a leading biopharmaceutical company focusing on the treatment of cancer and autoimmune diseases, announced to...
Suzhou Ribo Life Science Co., Ltd. (06938.HK), and its subsidiary Ribocure Pharmaceuticals AB (collectively referred to as "Ribo"), in collaboration with...
SK bioscience was selected to lead the Gates Foundation-funded ROTOR project, establishing a global collaboration framework. SK bioscience, PATH, Slal...
The University of California, Irvine (UC Irvine) School of Medicine and GlyTR Therapeutics have developed a next‑generation AAV‑mediated CAR T‑cell...
Following encouraging earlier-phase clinical data, the Company is advancing its acne trial ahead of schedule while maintaining atopic dermatitis global P...
© 2026 Biopharma Boardroom. All Rights Reserved.
